Combined modality therapy of Hodgkin's disease: 10-year results of National Cancer Institute of Canada Clinical Trials Group Multicenter Clinical Trial

Journal of Clinical Oncology

Volumn 9, Issue 11, 1991, Pages 1983-1993

  Yelle, L ^a   Bergsagel, D ^b   Basco, V ^b   Brown, T ^b   Bush, R ^b   Gillies, J ^b   Israels, L ^b   Miller, A ^b   Rideout, D ^b   Whitelaw, D ^b   Willan, A ^b   Pater, J ^b  

^a NOTRE DAME HOSPITAL   (Canada)

^b NONE

Author keywords

[No Author keywords available]

Indexed keywords

CHLORMETHINE; PREDNISONE; PROCARBAZINE; VINCRISTINE;

ADOLESCENT; ADULT; AGE; AGED; ARTICLE; CLINICAL TRIAL; CONTROLLED STUDY; FEMALE; HODGKIN DISEASE; HUMAN; MAJOR CLINICAL STUDY; MALE; PRIORITY JOURNAL; PROGNOSIS;

ADOLESCENT; ADULT; AGED; ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; COMBINED MODALITY THERAPY; COMPARATIVE STUDY; FEMALE; HODGKIN DISEASE; HUMAN; MALE; MECHLORETHAMINE; MIDDLE AGE; PREDNISONE; PROCARBAZINE; REGRESSION ANALYSIS; SURVIVAL ANALYSIS; VINCRISTINE;

EID: 0026094294     PISSN: 0732183X     EISSN: None     Source Type: Journal    
DOI: 10.1200/JCO.1991.9.11.1983     Document Type: Article

References (27)

1. DeVita VT, Serpick A: Combination chemotherapy in the treatment of advanced Hodgkin's disease. Proc Am Assoc Cancer Res 8:13. 1970 (ahstr)
2. Frei E III. Luce JK. Gamble JF, et al: Combination chemotherapy in advanced Hodgkin's disease. Ann Intern Med 7:376-382, 1973
3. Prosnitz LR. Farber LP, Fisher JJ. et al: Long term remission with combined modality therapy for advanced Hodgkin's disease. Cancer 37:2826-2833, 1976
4. Young RC. Canellos GP. Chabner BA. et al: Patterns of relapse in advanced Hodgkin's disease treated with combination chemotherapy. Cancer 42:1001-1007, 1978
5. Carbone PP, Kaplan HS, Musshoff K, et al: Report of the committee of Hodgkin's disease staging classification. Cancer Res 31:1860-1861, 1971
6. Dixon D, McLaughlin P, Hagemeister F, et al: Reporting outcomes in Hodgkin's disease and lymphoma. J Clin Oncol 5:1670-1672, 1987
7. Coppin C: The description of chemotherapy delivery: Options and pitfalls. Semin Oncol 14:34-42, 1987
8. Frei E III, Canellos GP: Dose: A critical factor in cancer chemotherapy. Am J Med 69:585-593, 1980
9. Goldie JH, Colman AJ: Quantitative model for multiple levels of drugs resistance in clinical tumors. Cancer Treat Rep 67:923-931, 1983
10. Hryniuk WM, Bush H: The importance of dose-intensity in chemotherapy of metastatic breast cancer. J Clin Oncol 2:1281-1288, 1987
11. Hryniuk WM, Figuredo A, Goodyear M: Applications of dose-intensity to problem in chemotherapy of breast and colorectal cancer. Semin Oncol 14:3-11, 1987
12. Levin L, Hryniuk W: The application of dose-intensity to problems in chemotherapy of ovarian and endometrial cancer. Semin Oncol 14:12-19, 1987
13. Murray N: The importance of dose-intensity in lung cancer chemotherapy. Semin Oncol 14:20-28, 1987
14. Pater JL: Introduction: Implications of dose-intensity for cancer clinical trials. Semin Oncol 14:1-2, 1987
15. Kaplan HS: Hodgkin's Disease, 2nd edition. Cambridge, MA, Harvard University, 1980, pp 689
16. Bergsagel DE. Alison RE. Bean HA, et al: Results of treating Hodgkin's disease without a policy of laparotomy staging. Cancer Treat Rep 66:717-731, 1982
17. Henry-Amar M, Aeppli DM, Anderson J, et al: Workshop statistical report, in Somers R, Henry-Amar M, Meerwaldt JK, et al (eds): Treatment Strategy in Hodgkin's Disease. London, UK, Libbey, 1990, pp 169-422
18. Bonadonna G, Valagussa P, Santoro A: Alternating non-cross resistant combination chemotherapy or MOPP in stage IV Hodgkin's disease. A report of 8 years. Ann Intern Med 104:739-746, 1986
19. Longo D, Young R, Weley M, et al: Twenty years of MOPP therapy for Hodgkin's disease. J Clin Oncol 4:1295-1306, 1986
20. Ruud EN, Rijswijk V. Haanen C, et al: Dose intensity of MOPP chemotherapy and survival in Hodgkin's disease. J Clin Oncol 7:1776-1782, 1985
21. Horning S: How much MOPP. J Clin Oncol 7:1766-1767, 1989 (letter)
22. Carde P, MacKintoch FR, Rosenberg SA: A dose and time response analysis of the treatment of Hodgkin's disease with MOPP chemotherapy. J Clin Oncol 1:146-153, 1983
23. Pillai N, Hagemeister FB, Velasquez WS, et al: Prognostic factors for stage IV Hodgkin's disease treated with MOPP, with or without bleomycin. Cancer 55:691-697, 1985
24. DeVita VT, Simon RM, Hubbard SM, et al: Curability of advanced Hodgkin's disease with chemotherapy. Long-term follow up of MOPP treated patients at NCT. Ann Intern Med 92:587-595, 1980
25. Dahlberg S, Miller TP, Dana B, et al: Dose intensity is not associated with subsequent survival after adjustment for known prognostic factors in non-Hodgkin's lymphoma patients treated with m-BACOD, ProMACE-CytaBOM, and MACOP-B on Southwest Oncology Group studies. Proc Am Soc Clin Oncol 9:255. 1990 (abstr)
26. Devita VT: The consequence of the chemotherapy of Hodgkin's disease: The 10th David A. Karnofsky Memorial Lecture. Cancer 47:1-13, 1981
27. Blayney DW, Longo DL, Young RC, et al: Decreasing risk of leukemia with prolonged follow-up after chemotherapy for Hodgkin's disease. N Engl J Med 316:710-714, 1987